These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18209600)

  • 21. Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis.
    Ravi S; Axley P; Jones D; Kodali S; Simpson H; McGuire BM; Singal AK
    Gastroenterology; 2017 Mar; 152(4):911-912. PubMed ID: 28161225
    [No Abstract]   [Full Text] [Related]  

  • 22. Histology of symptomatic acute hepatitis C infection in immunocompetent adults.
    Johnson K; Kotiesh A; Boitnott JK; Torbenson M
    Am J Surg Pathol; 2007 Nov; 31(11):1754-8. PubMed ID: 18059233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
    Chehadeh W; Al-Nakib W
    J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical aspects and diagnosis of hepatitis C].
    Leifeld L; Spengler U; Sauerbruch T
    Dtsch Med Wochenschr; 2000 Dec; 125(48):1471-4. PubMed ID: 11153417
    [No Abstract]   [Full Text] [Related]  

  • 25. HIV and hepatitis C coinfection.
    Matthews GV; Dore GJ
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1000-8. PubMed ID: 18707597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Latin American Association for the Study of the Liver Practice Guidelines. Diagnosis, management, and treatment of hepatitis C.
    Latin American Association for the Study of the Liver
    Ann Hepatol; 2010; 9 Suppl():8-26. PubMed ID: 20713990
    [No Abstract]   [Full Text] [Related]  

  • 27. Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications.
    Hui CK; Leung N; Shek WH; Zhang HY; Luk JM; Poon RT; Lo CM; Fan ST; Lau GK;
    J Clin Gastroenterol; 2008; 42(5):533-8. PubMed ID: 18344885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe hepatitis C recurrence: is it a negative predictive factor for sustained response to treatment?
    Oton E; Barcena R
    Gastroenterology; 2008 Jan; 134(1):367; author reply 367-8. PubMed ID: 18166372
    [No Abstract]   [Full Text] [Related]  

  • 29. Guide to care for patients. Hepatitis C.
    Nurse Pract; 2010 Jul; 35(7):9-10. PubMed ID: 20555235
    [No Abstract]   [Full Text] [Related]  

  • 30. [Epidemiologic and therapeutic status study of patients with hepatitis C].
    Xu M; Shi HY; Cai WP
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Apr; 25(2):135-6. PubMed ID: 21863640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation.
    Rigamonti C; Donato MF; Fraquelli M; Agnelli F; Ronchi G; Casazza G; Rossi G; Colombo M
    Gut; 2008 Jun; 57(6):821-7. PubMed ID: 18218676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma.
    La Mura V; De Renzo A; Perna F; D'Agostino D; Masarone M; Romano M; Bruno S; Torella R; Persico M
    J Hepatol; 2008 Oct; 49(4):557-63. PubMed ID: 18678434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Should trichrome stain be used on all post-liver transplant biopsies with hepatitis C virus infection to estimate the fibrosis score?
    Tretheway D; Jain A; LaPoint R; Sharma R; Orloff M; Milot P; Bozorgzadeh A; Ryan C
    Liver Transpl; 2008 May; 14(5):695-700. PubMed ID: 18324621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural history of hepatic fibrosis progression in chronic hepatitis C virus infection in India.
    Hissar SS; Kumar M; Tyagi P; Goyal A; Suneetha PV; Agarwal S; Rastogi A; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2009 Apr; 24(4):581-7. PubMed ID: 19032460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Fifteen years of investigations on hepatitis C virus in Poland].
    Juszczyk J
    Przegl Epidemiol; 2005; 59(2):373-84. PubMed ID: 16190544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.
    Bruno S; Zuin M; Crosignani A; Rossi S; Zadra F; Roffi L; Borzio M; Redaelli A; Chiesa A; Silini EM; Almasio PL; Maisonneuve P
    Am J Gastroenterol; 2009 May; 104(5):1147-58. PubMed ID: 19352340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of liver cancer with new curative hepatitis C antivirals: Real-world challenges.
    Soriano V; Tefferi A
    Cancer; 2018 Apr; 124(8):1647-1649. PubMed ID: 29486060
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of acute hepatitis C.
    Wallace MR
    Curr Gastroenterol Rep; 2002 Aug; 4(4):277-8. PubMed ID: 12149171
    [No Abstract]   [Full Text] [Related]  

  • 39. The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load.
    Arase Y; Suzuki F; Sezaki H; Kawamura Y; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Yatsuji H; Hirakawa M; Kobayashi M; Ikeda K; Kumada H
    Intervirology; 2008; 51(4):265-9. PubMed ID: 18841028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HCV genotype 3: a wolf in sheep's clothing.
    Blanco JR; Rivero-Juarez A
    Expert Rev Anti Infect Ther; 2016; 14(2):149-52. PubMed ID: 26635242
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.